key: cord-0869181-yu5g08xp
authors: Lim, Jeong-Hoon; Jung, Hee-Yeon; Choi, Ji-Young; Park, Sun-Hee; Kim, Chan-Duck; Kim, Yong-Lim; Cho, Jang-Hee
title: Hypertension and Electrolyte Disorders in Patients with COVID-19
date: 2020-12-28
journal: Electrolyte Blood Press
DOI: 10.5049/ebp.2020.18.2.23
sha: 7611f13bde6103b2ba76e39b2bad34066be1b682
doc_id: 869181
cord_uid: yu5g08xp

The worldwide coronavirus disease 2019 (COVID-19) pandemic is still in progress, but much remains unknown about the disease. In this article, we review the association of hypertension or the renin-angiotensin system (RAS) with COVID-19 and the correlation between electrolyte disorders and disease severity. Underlying hypertension is likely to be associated with severe or critical COVID-19, but the relationship is not clear owing to confounding factors. Angiotensin-converting enzyme 2 (ACE2) plays an important role in the non-classical RAS pathway and binds to a receptor binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The RAS blockade is known to increase ACE2 levels, but controversy remains regarding the effect of RAS blockade therapy in the course of COVID-19. Some reports have indicated a protective effect of RAS blockade on COVID-19, whereas others have reported an association of RAS blockade therapy with the occurrence of severe complications such as acute kidney injury and admission to the intensive care unit. Electrolyte disorders are not uncommon in patients with COVID-19, and severe COVID-19 has frequently shown hypokalemia, hyponatremia, and hypocalcemia. Electrolyte imbalances are caused by alteration of RAS, gastrointestinal loss, effects of proinflammatory cytokines, and renal tubular dysfunction by the invasion of SARS-CoV-2.

As the worldwide coronavirus disease 2019 (COVID- 19) pandemic continues, morbidity and mortality have increased 1, 2) . The pathogen responsible for COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel coronavirus belonging to the betacoronavirus genus and causes severe pneumonia in humans 2, 3) . There have been many studies to research SARS-CoV-2 around the world, and new information about this virus is continuously being updated.

Comorbid diseases such as diabetes and cardiovascular disease are known to increase the severity of COVID-19 1, 4) . Hypertension has also been reported to be associated with severe or critical disease in several studies [5] [6] [7] . It is presumed that the relationship between hypertension and severity of COVID-19 is related to angiotensin-converting enzyme 2 (ACE2) 7) . The spike protein of SARS-CoV-2 binds to ACE2 and causes depletion and downregulation of ACE2 8) .

Early epidemiological studies reported that electrolyte disorders are not uncommon in patients with COVID-19 9, 10) . Subsequent studies indicated that electrolyte imbalances were associated with more severe COVID-19 [11] [12] [13] . However, an individual study has limitations in interpretation owing to small sample sizes and ethnic differences. In the current study, we reviewed the latest information of COVID-19 to evaluate the association of hypertension or the renin-angiotensin system (RAS) with COVID-19 and the correla-

The entry of SARS-CoV-2 into target cells is facilitated by ACE2. Transmembrane ACE2 plays a role as an entry receptor by binding to the receptor binding domain of the virus's spike protein, thus allowing virus entry 14) . In addition, transmembrane protease serine subtype 2 (TMPRSS2) activates the spike protein to facilitate binding with ACE2, increasing virus invasion 8) . ACE2 is a new isoform of ACE discovered in 2000 15) and has a crucial role in the non-classical RAS pathway, ACE2/angiotensin (Ang)-(1-7)/Mas receptor axis, which counteracts the classical RAS pathway. ACE2 is not directly inhibited by conventional RAS inhibitors, such as ACE inhibitors (ACE-I) or angiotensin receptor blockers (ARB) 16) . The binding affinity of SARS-CoV-2 has been identified 10 to 20 times higher than SARS-CoV 17) . Therefore, ACE2 would play a more important role on infectivity in COVID-19. ACE2 is highly expressed on the colon, gall bladder, heart, kidney, and lung; therefore, these organs can be vulnerable to SARS-CoV-2 infection18). Serine protease, TMPRSS2, is highly expressed in epithelial cells in the prostate, colon, small intestine, kidney, and lung, and it is known to be upregulated by androgen 8) . ACE2 and TMPRSS2 coexpressed cells such as type 2 lung pneumocytes and ileal absorptive enterocytes are primary targets for virus invasion 8) .

Pathophysiological mechanisms of virus-induced multiorgan dysfunction have been identified as follows: (1) direct cytotoxicity of virus; (2) altered regulation of RAS by depletion and downregulation of ACE2; (3) endothelial cell injury, apoptosis, and thromboinflammation; and (4) dysregulation of immune response such as over-release of proinflammatory cytokines that cause cytokine storm 14) .

Early epidemiological studies reported that hypertension is common in patients with COVID-19 and is associated with disease severity 5, 6) . Of 1,099 patients with COVID-19 in China, hypertension was prevalent in nonsurvivors and severe COVID-19 patients (survivor vs nonsurvivor, 13.7% vs 35.8%; mild to moderate disease vs severe disease, 13.4% vs 23.7%) 9) . A meta-analysis of 2,552 Chinese patients with COVID-19 also reported that hypertension was associated with increased severity (odds ratio [OR], 2.49; 95% confidence interval [CI], 1.98-3.12) and mortality (OR, 2.42; 95% CI, 1.51-3.90) 19) . However, this evidence is still insufficient, mainly because of the retrospective design of the study and the presence of other comorbidities. Son et al. analyzed Korean population-based data and reported that the overall mortality rate of COVID-19 was 2.3% and that the mortality rate increased to 4.0% in COVID-19 patients with hypertension 20) . However, when comparing patients with hypertension who test negative for COVID-19, the mortality rate was not different between the 2 groups (hypertension with COVID 19 vs without COVID-19, 4.0% vs 3.9%; p=0.84) 20) . Patients with hypertension are usually older and often experience other comorbidities such as diabetes, cardiovascular disease, and obesity, which are also risk factors for disease severity in COVID-19 1, 4, 21, 22) . Therefore, it is difficult to interpret the independent effect of hypertension on severity of COVID-19. For these reasons, the Centers for Disease Control and Prevention (CDC) has not defined hypertension as a risk factor for severe COVID-19 23) . However, despite these limitations, many studies have reported and emphasized the impact of hypertension on COVID-19, and many researchers are still interested in the relationship between hypertension and COVID-19 because blood pressure could be changed after the modulation of ACE2 by SARS-CoV-2.

The RAS has a crucial role in maintaining blood pressure and electrolyte balance. There are 2 RAS pathways that counteract each other. In the classical RAS pathway, Ang I is converted to Ang II by ACE, which is expressed on the endothelial cells in the lung, kidney, heart, and brain 16) . Ang II activates Ang II type 1 receptor (AT1R), and AT1R induces several detrimental effects to the body, including vasoconstriction, inflammation, and fibrosis 16) . On the other hand, in the non-classical RAS pathway, ACE2 converts Ang I to Ang-(1-9) and Ang II to Ang-(1-7). Ang-(1-7) activates G pro-

tein-coupled receptor Mas and Mas receptor counteracts the detrimental effects of classical RAS pathway by induction of vasorelaxation, cardioprotection, anti-inflammation, and anti-oxidative action, especially in pathological conditions [24] [25] [26] [27] . ACE and ACE2 have principal roles in the RAS pathway by balancing both RAS pathways. In the experimental model, ACE2-deficient mice developed acute lung injury and acute respiratory distress syndrome (ARDS), and recombinant ACE2 protected mice from severe acute lung injury 28) . It has also been reported that Ang II level is elevated in patients with acute lung injury 29) , and that the elevated level of Ang II is associated with the severity of infection 30) . ACE2 acts as a receptor for the entry of SARS-CoV-2 into host cells through the process of endocytosis 16) . If SARS-CoV-2 invades the host cells and the immune system fails to defeat it, the virus reproduces rapidly and occupies ACE2 downregulating the production of functional ACE 28) . This induces upregulation of the classical RAS pathway and accelerates lung injury, inflammatory cytokine release, and systemic inflammation 8) .

There has been an emerging concern regarding the effect of ACE-Is and ARBs on the severity of COVID-19. ACE-Is and ARBs cannot directly affect the activity of ACE2, but they are known to increase the expression and activity of ACE2 by blocking the classical RAS pathway 31, 32) . If a patient with increased ACE2 expression by RAS blockade therapy is infected with SARS-CoV2, there are 2 possibilities in terms of the progression of the infection. First, increased ACE2 expression at the baseline would increase virus entry and infectivity, causing harmful effects. Second, activation of the non-classical RAS pathway and reduced action of the classical RAS pathway by increased ACE2 can cause beneficial effects on acute lung injury and systemic inflammation 33) . Several retrospective studies have analyzed which of these 2 effects of RAS blockade would be dominant in patients with COVID-19.

Despite a number of studies, there are still no consistent conclusions regarding the effects of RAS blockade therapy. In an early Chinese single-center, retrospective study, the authors reported a positive impact of RAS blockade therapy in COVID-19 34) . The study allocated patients with hypertension and COVID-19 into 2 groups according to the use of ACE-I or ARB and compared the disease severity and mortality between the groups. There were 43 patients in the ACE-I or ARB group and 83 patients in the non-ACE-I or ARB group. RAS blockade users showed significantly lower baseline high sensitivity C-reactive protein and procalcitonin levels (p=0.049 and p=0.038, respectively). Furthermore, the proportion of critically ill patients was lower in tendency (9.3% vs 22.9%; p=0.061).

However, most studies could not find any association between RAS blockade therapy and severe outcomes of COVID-19. A case-control study in Italy compared 6,272 COVID-19 patients with an age-and sex-matched general population 35) . After adjusting for medications and comorbid diseases, ACE-I or ARB therapy had a neutral impact on disease severity and mortality (all p>0.05). In a study from New York, propensity-score matched groups were compared, and none of the antihypertensive medications, including ACE-Is and ARBs, were found to be associated with COVID-19 severity 36) . Guo et al. performed a meta-analysis to evaluate the association between ACE-I or ARB therapy and mortality in COVID-19 37) . A total of 3,936 hypertensive patients with COVID-19 were included from 9 studies. In this study, ACE-I or ARB therapy was not associated with disease severity compared with nonmedication of ACE-I or ARB (OR, 0.71; 95% CI, 0.46-1.08). In another meta-analysis, 10,014 patients with COVID-19 were included from 13 studies. ACE-I or ARB therapy was not associated with disease severity (OR, 0.88; 95% CI, 0.60-1.31) or all-cause mortality (OR, 0.95; 95% CI, 0.57-1.58) 38) .

On the other hand, other studies have reported a negative impact of RAS blockade therapy. In a retrospective cohort study from France, 116 hospitalized COVID-19 patients who were admitted to the intensive care unit (ICU) or died in the hospital were analyzed 39) . After adjustment for age, sex, comorbid heart disease, and other antihypertensive medications, the risk of ICU admission or death was higher in the ACE-I or ARB therapy group than in the non-use group (OR, 1.73; 95% CI, 1.02-2.93). Another study in France also reported a negative impact of ACE-I or ARB use in patients with severe COVID-19 40) . In this study, 149 patients hos- Copyright © 2020 Korean Society for Electrolyte and Blood Pressure Research pitalized with COVID-19 were divided into an ACE-I or ARB group (n=44) and a no ACE-I or ARB group (n=105). ACE-I or ARB use independently increased the risk of acute kidney injury (OR, 3.28; 95% CI, 2.17-4.94), which is an independent risk factor for increased mortality in COVID-19 41, 42) .

A nationwide Korean population-based cohort study analyzed 1,954 hospitalized patients with COVID-19 43) . Among them, 377 patients used ACE-I or ARB, and those patients demonstrated a 3-fold higher in-hospital mortality rate (9% vs 3%; p<0.001). In addition, acute cardiac events such as cardiac arrest and acute heart failure were more frequent compared with nonusers (cardiac arrest: 2% vs 1%; p=0.01; acute heart failure: 10% vs 6%; p=0.02). We also analyzed 130 patients with severe COVID-19 in a retrospective cohort study 44) . The patients who received ACE-I or ARB showed an increased risk of both in-hospital mortality and severe complications such as ARDS and acute kidney injury. In particular, among the patients with ACE-I or ARB therapy, high equivalent doses of ACE-I or ARB was associated with higher in-hospital mortality.

In summary, it is still difficult to reach a definite conclusion regarding the effect of RAS blockade therapy in patients with COVID-19. All published data are from retrospective studies and have a limitation associated with the study design. The results may vary depending on whether the data were surveyed from epidemiological studies or extracted from the medical records. The different effects of RAS blockade among the various studies might also be attributable to ethnic differences in ACE2 expression. East Asian populations express higher ACE2 in tissues than other populations 45) . RAS blockade might induce ACE2 upregulation more prominently, affecting the prognosis of COVID-19 in Asian patients. There are several ongoing randomized controlled trials to identify the effects of ACE-I or ARB in patients with COVID-19 (NCT04338009, NCT04312009, and NCT04311177). The results from these prospective studies will help to conclude the effects of RAS blockade therapy.

Many studies have reported that electrolyte disorders accompany COVID-19 9, 10) . Lippi et al. conducted a meta-analysis to identify the association between electrolyte im-balances and the severity of COVID-19. They reported that hypokalemia, hyponatremia, and hypocalcemia were associated with severe COVID-19 46) . There are several causes of electrolyte disorders in patients with COVID-19. The first is altered RAS activation by downregulated ACE2. In the process of virus entry and replication, ACE2 is depleted and downregulated 8) . This causes a loss of antagonizing function of ACE2 against the classical RAS pathway and shifts the RAS balance toward the ACE/Ang II pathway 33) . Ang II activates AT1R, and AT1R induces renal sodium and water reabsorption. In addition, increased aldosterone causes increased urinary potassium excretion 16, 47) . Second, SARS-CoV-2 can invade renal tubular cells directly, thus causing tubular dysfunction. Proximal convoluted tubular epithelial cells and podocytes are known to coexpress ACE2 and TMPRSS2. Therefore, these cells are susceptible to virus invasion 48) . Virus particles were also identified in proximal tubules and podocytes of kidney by transmission electron microscope 49) . Third, gastrointestinal infection also contributes electrolyte imbalance. In early epidemiological studies, only 3% of COVID-19 patients had gastrointestinal symptoms 50) . However, recent studies have reported more common gastrointestinal manifestations among infected patients (9-11%) 51, 52) . As gastrointestinal tract cells have a high expression of ACE2 and mutation of the virus occurred during the replication process, these may increase gastrointestinal infection and cause electrolyte disorders 52) . These mechanisms act in combination, resulting in various electrolyte disorders.

Hypokalemia in COVID-19 is mainly caused by increased aldosterone concentration, which consequently induces an increased loss of potassium from urine 46, 53) . In an early epidemiology study from China, hypokalemia (≤3.5 mmol/L) was present in 54% (95 of 175) of COVID-19 patients on admission 11) . In particular, 18% (31 of 175) of patients had severe hypokalemia (<3 mmol/L) and had worse inflammatory indexes such as increased lactate dehydrogenase, C-reactive protein, and creatine kinase. The proportion of severe hypokalemia was higher in severely or critically ill patients than in mildly or moderately ill patients. Of interest, Copyright © 2020 Korean Society for Electrolyte and Blood Pressure Research mildly ill COVID-19 patients with hypokalemia achieved normokalemia within 5 to 8 days of potassium replacement, whereas correcting the potassium level in severely ill patients with hypokalemia was more difficult and required 10 to 14 days to achieve steady normokalemia 11) . This suggests that in severe COVID-19, activation of the classical RAS pathway increases the aldosterone level and that disease severity would be related to the degree of response to potassium replacement in hypokalemia.

The heart is also an organ vulnerable to SARS-CoV-2 invasion because of its high expression of ACE2 18) . Hypokalemia can trigger ventricular arrhythmia, which is a potentially life-threatening condition 11, 54) . The incidence of ventricular fibrillation is known to be 5-fold higher in patients with hypokalemia than those with hyperkalemia 55) . In hospitalized patients with COVID-19, it has been reported that ventricular fibrillation or ventricular tachycardia occurred in 8 out of 761 patients (1.1%) 56) . Taking these risks into account, potassium levels should be maintained above 4 mmol/L in COVID-19 patients with hypokalemia 11, 57) .

Hyponatremia is the most common electrolyte disorder among patients with COVID-19 and is mainly caused by syndrome of inappropriate secretion of antidiuretic hormone (SIADH) 58, 59) . Several lung pathologies such as ARDS, pneumonia, and pulmonary malignancy are well-known disorders that can cause SIADH 60) . Increased proinflammatory cytokine release such as interleukin (IL)-6 induces antidiuretic hormone (ADH) production by direct stimulation (nonosmotic ADH release). Indirect stimulation of IL-6 is mediated by an injury to the alveolar basement membrane, resulting in activation of hypoxic pulmonary vasoconstriction pathway that lead ADH release 61) . Hyponatremia caused by diarrhea in COVID-19 patients without respiratory symptoms has also been reported, and therefore gastrointestinal sodium loss should also be considered 62) . An Italian study evaluated the clinical impact of hyponatremia in COVID-19 12) . Hyponatremia was associated with more severe outcomes such as ICU admission or death, and serum sodium concentration demonstrated an inverse correlation with IL-6. In addition, when tocilizumab, a humanized monoclo-nal antibody against the IL-6 receptor, was administered in patients with hyponatremia, the serum sodium concentration was increased after 48 hours. This also supports the correlation between hyponatremia and IL-6 in patients with severe COVID-19.

Calcium ions (Ca 2+ ) play a crucial role in membrane fusion and the entrance of virus [63] [64] [65] [66] [67] . Several studies have reported that hypocalcemia is an independent risk factor for severe disease and long-term hospitalization in patients with COVID-19 13, 65, 68) . Previous studies have presented several explanations about the correlation between hypocalcemia and disease severity. First, a lower calcium concentration might reflect a higher viral load and lead to a prolonged period of virus shedding 65) . Second, serum calcium concentration is related to lung function and defense capacity against pathogenic microorganisms. Therefore, hypocalcemia may cause delayed recovery from pulmonary infection 65, 69, 70) . Third, hypocalcemia may be related to malnutrition. Chronic malnutrition causes vitamin D deficiency, which can lead to hypocalcemia, and therefore hypocalcemia patients would be vulnerable to infection 71) . Interestingly, dihydropyridine calcium channel blockers (CCBs) (nifedipine and amlodipine) improved mortality and also decreased risks for intubation and mechanical ventilation in a small retrospective study of 65 patients with COVID-19 72) . Similarly, in an experimental study, amlodipine, felodipine, and nifedipine also limited the growth of SARS-CoV-2 in the epithelial cells of the kidney (Vero E6) and lung (Calu-3) 73) . Future research is needed on the potential of CCBs to mitigate COVID-19.

Comorbid hypertension may be a risk factor for severe COVID-19, but the relationship cannot be clearly confirmed owing to limitations of the retrospective study design and various confounders. Although ACE2 plays an important role in COVID-19, the effects of RAS blockade therapy on COVID-19 remain uncertain. Patients who have been taking ACE-I or ARB are recommended to continue medication un-

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

Korean clinical practice guidelines for preventing transmission of coronavirus disease 2019 (COVID-19) in hemodialysis facilities

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel?

Clinical characteristics of coronavirus disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease

Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?

Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19

Extrapulmonary manifestations of COVID-19

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system

COVID-19 and RAS: unravelling an unclear relationship

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis

Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea

High prevalence of obesity in severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation

Obesity and COVID-19 severity in a designated hospital in Shenzhen

Control and Prevention: People who are at higher risk for severe illness

The ACE2/ angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin

Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system

Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive Rats

Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2-and NF-κB-dependent pathways

Angiotensin-converting enzyme 2 protects from severe acute lung failure

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syn-drome

Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan

ACE2 (angiotensin-converting enzyme 2), COVID-19, and ACE inhibitor and Ang II (angiotensin II) receptor blocker use during the pandemic

Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension

Reninangiotensin-aldosterone system blockers and the risk of COVID-19

Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19

Decreased mortality of COVID-19 with renin-angiotensin-aldosterone system inhibitors therapy in patients with hypertension

Outcomes of reninangiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis

Association between renin-angiotensin system inhibitors and COVID-19 complications

Long-term ACE inhibitor/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the North East of France

Acute kidney injury in critically ill patients with COVID-19

Fatal outcomes of COVID-19 in patients with severe acute kidney injury

Association of reninangiotensin-aldosterone system inhibitors with coronavirus disease 2019 (COVID-19)-related outcomes in Korea: a nationwide population-based cohort study

Adverse impact of reninangiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study

Comparative genetic analysis of the novel coronavirus (2019-nCoV/ SARS-CoV-2) receptor ACE2 in different populations

Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors

Acute kidney injury in SARS-CoV-2 infection: direct effect of virus on kidney proximal tubule cells

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

COVID-19 and the gastrointestinal tract: more than meets the eye

COVID-19, diabetes mellitus and ACE2: the conundrum

Hypokalaemia and subsequent hyperkalaemia in hospitalized patients

Hypokalemia and ventricular arrhythmias in acute myocardial infarction

In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan

What is the optimal serum potassium level in cardiovascular patients?

Analysis of early renal injury in COVID-19 and diagnostic value of multi-index combined detection

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus dis-ease 2019 (COVID-19): early report from the United States

The syndrome of inappropriate antidiuresis

COVID-19 pneumonia: an emerging cause of syndrome of inappropriate antidiuretic hormone

COVID-19 presenting with diarrhoea and hyponatraemia

Mechanisms of membrane fusion: disparate players and common principles

Rubella virus: first calcium-requiring viral fusion protein

Risk factors associated with long-term hospitalization in patients with COVID-19: a single-centered, retrospective study

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

Ca 2+ ions promote fusion of middle east respiratory syndrome coronavirus with host cells and increase infectivity

Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease

A multivariate analysis of serum nutrient levels and lung function

Calcium restores the macrophage response to nontypeable haemophilus influenzae in chronic obstructive pulmonary disease

Prevalence and predictive value of hypocalcemia in severe COVID-19 patients

Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19

FDA approved calcium channel blockers inhibit SARS CoV 2 infectivity in epithelial lung cells